6589 | 台康生技 - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates 6589 with a lower value score of 2.
It is mainly due to insufficient operating cash flow, along with lower ROE.
Over the past 3 months, 6589 has maintained a consecutive value rating of 2.0, slightly lower than the rating of 2.6 over the past 3 years, indicating slight decrease in enterprise value.
Compared to all stocks in the Biotech. & Medical sector, 6589 has a medium value rating.

6589 Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/21 (Weekly Update)

6589 Financial Forecast

Unit : TWD

Update to 2025/5/9 (Quarterly Update)

6589 Earnings Table

Unit : TWD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	-0.38	71.4%	17.4%	294.64M	-35.5%	35.2%	-39.9%
2024Q3	-0.84	-127%	2.3%	248.22M	17.4%	0.1%	-103.2%
2024Q2	-0.72	-12.5%	-71.4%	246.4M	78.1%	-14.4%	-47.3%
2024Q1	-1.33	-98.5%	-2,560%	456.57M	111.1%	29.3%	-47.3%
2023Q4	-1.33	-98.5%	-2,560%	456.57M	111.1%	29.3%	-88.9%

Update to 2025/5/11 (Quarterly Update)

6589 Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

6589 Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of 6589 from 2019/06 till Now

25.00%
Cumulative Return: 4.03%
Annual Return: 22.20%
Volatility: 0.18
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from June, 2019 to May, 2025. (Total Trades: 1)